| 26.08 -0.21 (-0.8%) | 11-11 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.75 | 1-year : | 34.59 |
| Resists | First : | 28.04 | Second : | 29.62 |
| Pivot price | 27.4  |
|||
| Supports | First : | 25.48 | Second : | 21.2 |
| MAs | MA(5) : | 26.56 |
MA(20) : | 27.52 |
| MA(100) : | 24.65 |
MA(250) : | 24.76 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 14.3 |
D(3) : | 20 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 29.62 | Low : | 19.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BLFS ] has closed above bottom band by 8.6%. Bollinger Bands are 2.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.62 - 26.77 | 26.77 - 26.9 |
| Low: | 25.6 - 25.8 | 25.8 - 25.97 |
| Close: | 26.01 - 26.29 | 26.29 - 26.55 |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Sun, 09 Nov 2025
BioLife Solutions (BLFS) Refocuses on Cell Processing After Evo Sale—Is Its Core Platform Ready to Scale? - simplywall.st
Sun, 09 Nov 2025
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2025 Earnings Call Transcript - Insider Monkey
Sat, 08 Nov 2025
Why BioLife Solutions (BLFS) Is Up After Raising 2025 Guidance and Sharpening Its Cell Processing Focus - Yahoo Finance
Fri, 07 Nov 2025
BioLife Solutions Reports Strong Q3 Earnings Growth - TipRanks
Fri, 07 Nov 2025
Beyond the Balance Sheet: What SWOT Reveals About BioLife Soluti - GuruFocus
Fri, 07 Nov 2025
BioLife Solutions Inc (BLFS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 48 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 3,370 (K) |
| Shares Short P.Month | 3,930 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.26 |
| Profit Margin | -6 % |
| Operating Margin | -4.5 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -5.7 % |
| Qtrly Rev. Growth | 28.8 % |
| Gross Profit (p.s.) | 1.26 |
| Sales Per Share | 1.95 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 16 (M) |
| Levered Free Cash Flow | 31 (M) |
| PE Ratio | -65.06 |
| PEG Ratio | 0 |
| Price to Book value | 3.58 |
| Price to Sales | 13.33 |
| Price to Cash Flow | 80.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|